Statin-fibrate combination therapy

Annals of Pharmacotherapy

Volumn 35, Issue 7-8, 2001, Pages 908-917

  Shek, A ^a   Ferrill, M J ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

Fibrates; Interaction; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CLINICAL TRIAL; DRUG CONTRAINDICATION; FEMALE; HUMAN; HYPERLIPIDEMIA; MALE; MONOTHERAPY; MUSCLE INJURY; MYOPATHY; PATIENT COUNSELING; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK FACTOR;

EID: 0034924212     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10315     Document Type: Article

References (99)

1. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
2. Epidemiology of hypertriglyceridemia and cardiovascular disease
3. 27th Bethesda conference. Matching the intensity of risk factor management with the hazard for coronary disease events. September 14-15, 1995
4. Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen Male Study
5. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment
6. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
7. A prospective study of triglyceride concentration, low-density lipoprotein particle diameter, and risk of myocardial infarction
8. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease
9. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention
10. The American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis
11. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: Comparative analysis with a fluvastatin-cholestyramine combination
12. Fibrates and statins in the treatment of hyperlipidemia: An appraisal of their efficacy and safety
13. Drugs used in the treatment of hyperlipoproteinemias
14. Diabetic dyslipidemia
15. Niacin: A therapeutic dilemma. "One man's drink is another's poison"
16. Experience with crystalline niacin as the preferred drug for dyslipidemia in a specialty clinic
17. Pathophysiology and management of low high-density lipoprotein cholesterol
18. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: Additive effects of combination treatment on lipid regulation
19. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia
20. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias
21. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole
22. Lovastatin and rhabdomyolysis
23. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients
24. Dual hepatic metabolism of cerivastatin - Clarifications
25. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia
26. The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis
27. Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozil therapy
28. Lovastatin/gemfibrozil myopathy: A clinical, histochemical, and ultrastructural study
29. Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants
30. Rhabdomyolysis and renal failure secondary to combination therapy of hyperlipidemia with lovastatin and gemfibrozil
31. Lovastatin-induced acute rhabdomyolysis
32. Cholesterol-lowering agent myopathy (CLAM)
33. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil
34. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy
35. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy
36. Rhabdomyolysis with simvastatin use
37. Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease
38. Acute compartment syndrome: An unusual presentation of gemfibrozil induced myositis
39. Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy
40. Gemfibrozil-induced myopathy
41. Rhabdomyolysis secondary to lovastatin therapy
42. Rhabdomyolysis and simvastatin
43. Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs
44. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil
45. Rhabdomyolysis after taking atorvastatin with gemfibrozil
46. Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics
47. HMG-CoA reductase inhibitors and fibric acid derivatives: A dangerous combination for the treatment of hyperlipidemia
48. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy
49. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil
50. Efficacy and safety of cerivastatin/bezafibrate combination therapy for dyslipidemia
51. Efficacy and safety of cerivastatin/fenofibrate combination therapy for hypercholesterolemia
52. Safety of combined pravastatin-gemfibrozil therapy
53. Effects of combined bezafibrate-simvastatin appraised in healthy subjects
54. Combined hyperlipidemia is associated with increased exercise-induced muscle protein release which is improved by triglyceride-lowering intervention
55. Fluvastatin in familial hypercholesterolemia: A cohort analysis of the response to combination treatment
56. Treatment of hyperlipidemia in heart transplant recipients with gemfibrozil ± lovastatin
57. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia
58. Combined treatment with pravastatin and gemfibrozil in patients with refractory familial combined hyperlipidaemia. A clinical study
59. Tolerability and efficacy of combination therapy with simvastatin plus gemfibrozil in type IIb refractory familial combined hyperlipidemia
60. Combination drug therapy for familial combined hyperlipidemia
61. The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia
62. Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM
63. Safety and efficacy of combined gemfibrozil-lovastatin therapy for primary dyslipoproteinemias
64. Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias
65. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities
66. Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia
67. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders
68. Long-term treatment with pravastatin alone and in combination with gemfibrozil in familial type IIb hyperlipoproteinemia or combined hyperlipidemia
69. Effect of combination therapy with lipid-reducing drags in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial
70. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage
71. Pharmacokinetics of the combination of fluvastatin and gemfibrozil
72. Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination
73. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia
74. A retrospective review of the use of lipid-lowering agents in combination, specifically, gemfibrozil and lovastatin
75. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia
76. Addition of fibrates to simvastatin therapy in hyperlipidaemic patients
77. High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia
78. Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia
79. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia
80. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia
81. Treatment of primary hypercholesterolaemia with simvastatin: New Zealand multicenter evaluation
82. The hypolipidaemic effects of pravastatin (CS-514) alone and in combination with bezafibrate or acipimox in patients with primary hypercholesterolaemia
83. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels
84. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination
85. Statin + fibrate combination therapy. Fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease
86. Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease
87. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease
88. The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia
89. Simvastatin in combination with other lipid lowering drugs (colestipol and fenofibrate): Effects on serum lipoproteins
90. Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism
91. Treatment of hyperlipidemia with combined niacin-statin regimens
92. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT Study: A randomized trial